Pretreatment with valproic acid, a histone deacetylase inhibitor, enhances the sensitivity of the peripheral blood micronucleus assay in rodents

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 751, Issue 1, 2013, Pages 19-26

  Ahmad, T ^a   Shekh, K ^a   Khan, S ^a   Vikram, A ^a   Yadav, L ^a   Parekh, C V ^a   Jena, G B ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Cyclophosphamide; Methotrexate; Micronuclei; Valproic acid; Zidovudine

Indexed keywords

CYCLOPHOSPHAMIDE; METHOTREXATE; VALPROIC ACID; ZIDOVUDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD; CONTROLLED STUDY; DNA DAMAGE; ERYTHROCYTE; GENOTOXICITY; MALE; MICRONUCLEUS TEST; MOUSE; NONHUMAN; PREMEDICATION; PRIORITY JOURNAL; RAT; RETICULOCYTE; TREATMENT DURATION;

ANIMALS; CYCLOPHOSPHAMIDE; ERYTHROCYTES; HISTONE DEACETYLASE INHIBITORS; MALE; METHOTREXATE; MICE; MICRONUCLEUS TESTS; MUTAGENS; RATS; RATS, SPRAGUE-DAWLEY; RETICULOCYTES; SENSITIVITY AND SPECIFICITY; VALPROIC ACID; ZIDOVUDINE;

MUS; RATTUS; RODENTIA;

EID: 84873472536     PISSN: 13835718     EISSN: 18793592     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2012.10.009     Document Type: Article

References (33)

1. Purves D., Harvey C., Tweats D., Lumley C.E. Genotoxicity testing: current practices and strategies used by the pharmaceutical industry. Mutagenesis 1995, 10:297-312.
2. Pfuhler S., Albertini S., Fautz R., Herbold B., Madle S., Utesch D., Poth A. Genetic toxicity assessment: employing the best science for human safety evaluation part IV: recommendation of a working group of the Gesellschaft fuer Umwelt-Mutationsforschung (GUM) for a simple and straightforward approach to genotoxicity testing. Toxicol. Sci. 2007, 97:237-240.
3. Vasquez M.Z. Combining the in vivo comet and micronucleus assays: a practical approach to genotoxicity testing and data interpretation. Mutagenesis 2010, 25:187-199.
4. Zhu S., Wang A., Xia Z. Polymorphisms of DNA repair gene XPD and DNA damage of workers exposed to vinylchloride monomer. Int. J. Hyg. Environ. Health 2005, 208:383-390.
5. Witt K.L., Knapton A., Wehr C.M., Hook G.J., Mirsalis J., Shelby M.D., MacGregor J.T. Micronucleated erythrocyte frequency in peripheral blood of B6C3F(1) mice from short-term, prechronic, and chronic studies of the NTP carcinogenesis bioassay program. Environ. Mol. Mutagen. 2000, 36:163-194.
6. Suzuki T., Hayashi M., Hakura A., Asita A.O., Kodama Y., Honma M., Sofuni T. Combination effects of clastogens in the mouse peripheral blood micronucleus assay. Mutagenesis 1995, 10:31-36.
7. Ramirez-Munoz M.P., Zuniga G., Torres-Bugarin O., Portilla E., Garcia-Martinez D., Ramos A., Cantu J.M., Sanchez-Corona J. Evaluation of the micronucleus test in peripheral blood erythrocytes by use of the splenectomized model. Lab. Anim. Sci. 1999, 49:418-420.
8. Schlegel R., MacGregor J.T. The persistence of micronucleated erythrocytes in the peripheral circulation of normal and splenectomized Fischer 344 rats: implications for cytogenetic screening. Mutat. Res. 1984, 127:169-174.
9. Vikram A., Ramarao P., Jena G. Prior bleeding enhances the sensitivity of peripheral blood and bone marrow micronucleus tests in rats. Mutagenesis 2007, 22:287-291.
10. Dertinger S.D., Torous D.K., Tometsko K.R. Induction of micronuclei by low doses of azidothymidine (AZT). Mutat. Res. 1996, 368:301-307.
11. Torous D.K., Hall N.E., Illi-Love A.H., Diehl M.S., Cederbrant K., Sandelin K., Ponten I., Bolcsfoldi G., Ferguson L.R., Pearson A., Majeska J.B., Tarca J.P., Hynes G.M., Lynch A.M., McNamee J.P., Bellier P.V., Parenteau M., Blakey D., Bayley J., van der Leede B.J., Vanparys P., Harbach P.R., Zhao S., Filipunas A.L., Johnson C.W., Tometsko C.R., Dertinger S.D. Interlaboratory validation of a CD71-based flow cytometric method (Microflow) for the scoring of micronucleated reticulocytes in mouse peripheral blood. Environ. Mol. Mutagen. 2005, 45:44-55.
12. Torous D.K., Hall N.E., Murante F.G., Gleason S.E., Tometsko C.R., Dertinger S.D. Comparative scoring of micronucleated reticulocytes in rat peripheral blood by flow cytometry and microscopy. Toxicol. Sci. 2003, 74:309-314.
13. Witt K.L., Livanos E., Kissling G.E., Torous D.K., Caspary W., Tice R.R., Recio L. Comparison of flow cytometry- and microscopy-based methods for measuring micronucleated reticulocyte frequencies in rodents treated with nongenotoxic and genotoxic chemicals. Mutat. Res. 2008, 649:101-113.
14. Vikram A., Tripathi D.N., Pawar A.A., Ramarao P., Jena G.B. Pre-bled-young-rats in genotoxicity testing: a model for peripheral blood micronucleus assay. Regul. Toxicol. Pharmacol. 2008, 52:147-157.
15. Mughal A., Vikram A., Kushwaha S., Jena G.B. Simultaneous use of erythropoietin and prior bleeding enhances the sensitivity of the peripheral blood micronucleus assay. Mutagenesis 2011, 26:331-338.
16. Davis R., Peters D.H., McTavish D. Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994, 47:332-372.
17. Nasrallah H.A., Ketter T.A., Kalali A.H. Carbamazepine and valproate for the treatment of bipolar disorder: a review of the literature. J. Affect. Disord. 2006, 95:69-78.
18. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002, 16:695-714.
19. Khan S., Ahmad T., Parekh C.V., Trivedi P.P., Kushwaha S., Jena G. Investigation on sodium valproate induced germ cell damage, oxidative stress and genotoxicity in male Swiss mice. Reprod. Toxicol. 2011, 32:385-394.
20. Marchion D.C., Bicaku E., Daud A.I., Sullivan D.M., Munster P.N. In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol. Cancer Ther. 2005, 4:1993-2000.
21. Duenas-Gonzalez A., Candelaria M., Perez-Plascencia C., Perez-Cardenas E., de la Cruz-Hernandez E., Herrera L.A. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat. Rev. 2008, 34:206-222.
22. Carew J.S., Giles F.J., Nawrocki S.T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 2008, 269:7-17.
23. Marchion D.C., Bicaku E., Daud A.I., Sullivan D.M., Munster P.N. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res. 2005, 65:3815-3822.
24. Fuskevag O.M., Kristiansen C., Lindal S., Aarbakke J. Maximum tolerated doses of methotrexate and 7-hydroxy-methotrexate in a model of acute toxicity in rats. Cancer Chemother. Pharmacol. 2000, 46:69-73.
25. Ozawa A., Tanji N., Kikugawa T., Sasaki T., Yanagihara Y., Miura N., Yokoyama M. Inhibition of bladder tumour growth by histone deacetylase inhibitor. BJU Int. 2010, 105:1181-1186.
26. Hayashi M., MacGregor J.T., Gatehouse D.G., Blakey D.H., Dertinger S.D., Abramsson-Zetterberg L., Krishna G., Morita T., Russo A., Asano N., Suzuki H., Ohyama W., Gibson D. In vivo erythrocyte micronucleus assay III. Validation and regulatory acceptance of automated scoring and the use of rat peripheral blood reticulocytes, with discussion of non-hematopoietic target cells and a single dose-level limit test. Mutat. Res. 2007, 627:10-30.
27. Fenech M., Holland N., Chang W.P., Zeiger E., Bonassi S. The HUman MicroNucleus Project-an international collaborative study on the use of the micronucleus technique for measuring DNA damage in humans. Mutat. Res. 1999, 428:271-283.
28. Szyf M. The dynamic epigenome and its implications in toxicology. Toxicol. Sci. 2007, 100:7-23.
29. Munster P., Marchion D., Bicaku E., Lacevic M., Kim J., Centeno B., Daud A., Neuger A., Minton S., Sullivan D. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin. Cancer Res. 2009, 15:2488-2496.
30. Arce C., Perez-Plasencia C., Gonzalez-Fierro A., de la Cruz-Hernandez E., Revilla-Vazquez A., Chavez-Blanco A., Trejo-Becerril C., Perez-Cardenas E., Taja-Chayeb L., Bargallo E., Villarreal P., Ramirez T., Vela T., Candelaria M., Camargo M.F., Robles E., Duenas-Gonzalez A. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS ONE 2006, 1:e98.
31. Rocca A., Minucci S., Tosti G., Croci D., Contegno F., Ballarini M., Nole F., Munzone E., Salmaggi A., Goldhirsch A., Pelicci P.G., Testori A. A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br. J. Cancer 2009, 100:28-36.
32. Kim M.S., Blake M., Baek J.H., Kohlhagen G., Pommier Y., Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 2003, 63:7291-7300.
33. Baer B.R., Rettie A.E. CYP4B1: an enigmatic P450 at the interface between xenobiotic and endobiotic metabolism. Drug Metab. Rev. 2006, 38:451-476.